Phase 2/3RecruitingHealthspan endpoint

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Sponsor
University of Colorado, Denver (Academic or other)
Enrollment
200 planned
Conditions
Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular
Interventions
Metformin; semaglutide; Anti-hypertensives; Lipid Lowering Medication; Life style intervention; Fezolinetant; Hormonal therapy
Ages
adults
Registry
NCT06975111

Full record on ClinicalTrials.gov

From the registry

What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.

Primary outcomes

  • Epigenetic aging measurements of "PhenoAge"
  • Epigenetic aging measurements of "GrimAge"

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered

In the news